For example, KRAS mutations, more than 90% of low-grade PanINs harbor the mutations of this, would be representative screening biomarkers in individuals at high risk of pancreatic cysts or apparently normal pancreas. The gene discussed is KRAS; the disease is Pancreatic cysts.